Total Human Chorionic Gonadotropin is a More Suitable Diagnostic Marker of Gestational Trophoblastic Diseases Than the Free β-subunit of Human Chorionic Gonadotropin

Overview

Journal Pract Lab Med

Specialty Biochemistry

Date 2023 Nov 29

PMID 38025990

Authors

Hirokazu Usui

Atsuko Mikiya

Eri Katayama

Natsuko Nakamura

Asuka Sato

Hideo Matsui

Makio Shozu

Kaori Koga

Affiliations

Soon will be listed here.

Abstract

Objectives: Human chorionic gonadotropin (hCG) levels are essential for the management of trophoblastic diseases. This study aimed to compare the sensitivities and relationships of two hCG measurement methods (total hCG and the free β-subunit of hCG) in managing gestational trophoblastic disease (GTD).

Design And Methods: We analyzed data from patients treated for GTD at Chiba University Hospital between 2008 and 2019. We focused on cases where both total hCG (mIU/mL) and the free β-subunit of hCG (ng/mL) were measured on the same day.

Results: Out of 80 patients (mean age 38.9 ± 11.7 years) and 158 measurements, 26 had values below the sensitivity threshold for both tests. Fifty-nine measurements were positive for total hCG but below the sensitivity threshold for the free β-subunit of hCG, whereas only two showed the opposite. Seventy-one measurements were positive for both total hCG and the free β-subunit of hCG. There was a significant correlation between total hCG and the free β-subunit of hCG with both positive values, (r = 0.94, p < 0.001; Spearman's correlation test). Of the 85 measurements with undetectable free β-subunit levels, 26 also had undetectable total hCG levels. However, total hCG was detectable in 59 patients from these cases, with a median value (interquartile range) of 2.9 (1.75-4.9) mIU/mL.

Conclusions: In the management of GTD, the use of the free β-subunit system alone cannot be recommended.

References

Gillessen S, Sauve N, Collette L, Daugaard G, de Wit R, Albany C . Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021; 39(14):1563-1574. PMC: 8099402. DOI: 10.1200/JCO.20.03296. View

de Medeiros S, Norman R . Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights. Hum Reprod Update. 2008; 15(1):69-95. DOI: 10.1093/humupd/dmn036. View

Birken S, Berger P, Bidart J, Weber M, Bristow A, Norman R . Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin Chem. 2003; 49(1):144-54. DOI: 10.1373/49.1.144. View

Marcillac I, Troalen F, Bidart J, Ghillani P, Ribrag V, Escudier B . Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res. 1992; 52(14):3901-7. View

McMahon L, Joyce C, Cuthill L, Mitchell H, Jabbar I, Sweep F . Measurement of Human Chorionic Gonadotrophin in Women with Gestational Trophoblastic Disease. Gynecol Obstet Invest. 2023; 89(3):178-197. PMC: 11151977. DOI: 10.1159/000531499. View

Canick J, Lambert-Messerlian G, Palomaki G, Neveux L, Malone F, Ball R . Comparison of serum markers in first-trimester down syndrome screening. Obstet Gynecol. 2006; 108(5):1192-9. DOI: 10.1097/01.AOG.0000241095.19638.f2. View

Lok C, van Trommel N, Massuger L, Golfier F, Seckl M . Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020; 130:228-240. DOI: 10.1016/j.ejca.2020.02.011. View

Stenman U, Alfthan H . Determination of human chorionic gonadotropin. Best Pract Res Clin Endocrinol Metab. 2013; 27(6):783-93. DOI: 10.1016/j.beem.2013.10.005. View

Ozturk M, Bellet D, Manil L, Hennen G, Frydman R, Wands J . Physiological studies of human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by specific monoclonal immunoradiometric assays. Endocrinology. 1987; 120(2):549-58. DOI: 10.1210/endo-120-2-549. View

10.

Cole L, Shahabi S, Butler S, Mitchell H, Newlands E, Behrman H . Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases. Clin Chem. 2001; 47(2):308-15. View

11.

Berkowitz R, Ozturk M, Goldstein D, Bernstein M, Hill L, Wands J . Human chorionic gonadotropin and free subunits' serum levels in patients with partial and complete hydatidiform moles. Obstet Gynecol. 1989; 74(2):212-6. View

12.

. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15(2):594-603. DOI: 10.1200/JCO.1997.15.2.594. View

13.

Hoshi S, Suzuki K, Ishidoya S, Ohyama C, Sato M, Namima T . Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients. Int J Urol. 2000; 7(6):218-23. DOI: 10.1046/j.1442-2042.2000.00181.x. View

14.

Cole L . Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. Clin Chem. 1998; 43(12):2233-43. View

15.

Lempiainen A, Stenman U, Blomqvist C, Hotakainen K . Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. Clin Chem. 2008; 54(11):1840-3. DOI: 10.1373/clinchem.2008.108548. View

16.

Cole L, Sutton J . Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. J Reprod Med. 2004; 49(7):545-53. View

17.

Soper J . Gestational Trophoblastic Disease: Current Evaluation and Management. Obstet Gynecol. 2021; 137(2):355-370. PMC: 7813445. DOI: 10.1097/AOG.0000000000004240. View

18.

Seckl M, Sebire N, Berkowitz R . Gestational trophoblastic disease. Lancet. 2010; 376(9742):717-29. DOI: 10.1016/S0140-6736(10)60280-2. View

19.

Pretorius C, Wilgen U, Klingberg S, Zournazi A, Sanders L, Ungerer J . Comparison between free β subunit of human chorionic gonadotropin (hCG) and total hCG assays in adults with testicular cancer. Clin Chem Lab Med. 2023; 61(10):1841-1849. DOI: 10.1515/cclm-2022-1240. View

20.

. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet. 2002; 77(3):285-7. DOI: 10.1016/s0020-7292(02)00063-2. View